查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1877473

凝血障礙市場：依類型、治療方法、檢測方法、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2025-2032年預測

Coagulation Disorders Market, By Type, By Treatment, By Test, By End Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 387 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年凝血障礙市場規模為 105.6789 億美元，從 2025 年到 2032 年以 6.8% 的複合年成長率成長。

凝血障礙市場的發展主要受出血和凝血障礙盛行率上升以及基因療法和重組凝血因子等個人化醫療技術的進步所驅動。人工智慧在診斷和管理中的應用，透過預測分析和個人化監測最佳化治療方案，預計將在預測期內為市場帶來豐厚的機會。此外，數位化醫療解決方案透過促進遠距監測和遠距醫療諮詢，提高了患者的便利性，增強了患者的依從性，並改善了治療效果。然而，供應鏈中斷和醫療基礎設施的地域差異對市場擴張構成挑戰。此外，高昂的治療成本、監管方面的挑戰以及新型檢測技術普及速度緩慢也限制市場成長。

凝血障礙市場－市場動態

基因療法和個人化醫療的日益普及

血友病和其他罕見出血性疾病歷來需要反覆輸注重組或血漿來源的凝血因子。然而，這些治療費用昂貴，需要終身護理，並且有產生抑制劑的風險。基因療法現在有望透過插入缺陷基因的功能性拷貝，一次性、長期地糾正凝血因子缺乏症。例如，2023年6月，美國FDA批准了用於治療血友病A的Roctavian（BioMarin公司）和用於治療血友病B的Hemgenix（CSL Behring/UniQure公司）等基因療法。血友病A是一種罕見的遺傳性疾病，其特徵是凝血因子VIII（FVIII）缺乏，導致出血時間延長，並可能引發危及生命的併發症，例如無法控制的內出血和關節損傷。此外，個人化醫療透過根據個別基因譜量身定做治療方案，進一步促進了這一轉變，從而實現精準治療並最大限度地減少不良反應。分子診斷技術的進步，包括基因檢測和下一代定序 (NGS)，有助於早期診斷和患者分層，從而根據患者的特定特徵匹配最合適的療法，提高治療效果。

凝血障礙市場細分分析：

全球凝血障礙市場按類型、治療、檢測、最終用戶和地區進行細分。

依類型，市場分為五大類：血友病A、血友病B、血管性血友病、因子II、V、X、XII缺乏症及其他。血友病A是一種遺傳性疾病，其特徵是凝血因子VIII缺乏；血友病B則涉及因子IX缺乏，症狀與之類似。血管性血友病是由於血管性血友病因子水平低下或缺陷所致，影響血液凝固並導致黏膜出血。因子II、V、X、XII缺乏症是一種罕見的凝血障礙，涉及其他凝血因子，導致不同程度的出血症狀。

根據治療方法，市場可分為三大類：補鐵、輸血和其他。補鐵用於治療慢性失血引起的貧血。輸血則用於補充流失的血液並促進凝血因子恢復。凝血因子替代療法、去氨加壓素、抗凝血藥物、基因療法和非凝血因子療法則根據疾病類型和嚴重程度製定個人化治療方案。

凝血障礙市場－地域洞察

凝血障礙市場呈現明顯的地域性趨勢，主要受醫療基礎設施、疾病盛行率和區域投資的影響。北美市場佔據主導地位，這得益於凝血障礙的高發病率、完善的醫療保健體係以及強勁的研發活動。此外，血漿採集中心投資的增加也進一步推動了市場成長。歐洲市佔率位居第二，德國、英國、法國、義大利和西班牙等國貢獻顯著。該地區的成長得益於廣泛的研究合作、法規核准以及患者較高的健康意識。人口老化和診斷技術的進步也促使人們對凝血障礙治療的需求不斷成長。亞太地區是成長最快的地區，這主要得益於中國、印度和日本不斷成長的醫療保健支出、快速的城市化進程以及不斷擴大的醫療基礎設施。由於醫療資源取得和健康意識的不足，中東、非洲和拉丁美洲等地區的成長速度相對較慢。然而，隨著醫療保健技術的不斷進步和國際合作的開展，這些地區也展現出巨大的發展潛力。

凝血障礙市場－競爭格局：

凝血障礙市場的競爭格局以多家全球領導者為特徵，這些企業正透過先進的療法和診斷解決方案推動創新。主要市場參與者致力於開發創新治療方案，例如基因療法、長效重組凝血因子、單株抗體和生物相似藥，以改善患者的治療效果和生活品質。例如，2024年4月，Haemonetics公司宣布其TEG 6s止血分析儀系統的Global Hemostasis-HN檢測盒已獲得美國食品藥物管理局（FDA）的510(k)許可。這款新型檢測盒擴展了TEG 6s系統的黏彈性檢測功能，使其能夠檢測接受成人心血管手術和肝臟移植的全身肝素化患者。此外，無血漿重組產品的普及以及CRISPR等基因編輯技術的進步也是影響市場競爭格局的關鍵趨勢。各公司也正在投資即時診斷工具和穿戴式凝血監測設備，推動醫療服務朝向個人化和便利化方向發展。為了拓展產品組合和區域影響力，企業之間進行策略合作、合併和收購已成為常態。

目錄

第1章：凝血障礙市場概覽

  • 研究範圍
  • 市場估算年份

第2章：執行概要

  • 市集
    • 凝血障礙市場概況（按類型分類）
    • 凝血障礙治療市場概覽
    • 凝血障礙市場概覽（依測驗分類）
    • 凝血障礙市場概覽（依終端使用者分類）
    • 各國凝血障礙市場概況
    • 凝血障礙市場概況（按地區分類）
  • 競爭洞察

第3章：凝血障礙主要市場趨勢

  • 凝血障礙市場促進因素
    • 市場促進因素的影響分析
  • 凝血障礙市場限制
    • 市場限制因素的影響分析
  • 凝血障礙市場機遇
  • 凝血障礙市場未來趨勢

第4章：凝血障礙產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景分析
  • 規範架構分析

第5章：凝血障礙市場：地緣政治緊張局勢升級的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：凝血障礙市場概況

  • 凝血障礙市場佔有率分析，2024 年
  • 主要製造商細分數據
    • 知名球員分析
    • 新興參與者分析

第7章：凝血障礙市場－按類型分類

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 血友病A
    • 血友病B
    • 血管性血友病
    • 因子 II、V、X、XII 缺乏症
    • 其他

第8章：凝血障礙市場－依治療方式分類

  • 概述
    • 按治療方式分類的細分市場佔有率分析
    • 鐵補充劑
    • 輸血
    • 其他

第9章：凝血障礙市場－依檢測方式分類

  • 概述
    • 測試版細分市場佔有率分析
    • 全血球計數 (CBC)
    • 血小板聚集試驗
    • 纖維蛋白原測定
    • 凝血酶原時間試驗
    • 其他

第10章：凝血障礙市場－依最終使用者分類

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 專科診所
    • 診斷中心
    • 血庫
    • 其他

第11章：凝血障礙市場－依地域分類

  • 介紹
    • 按地域分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美凝血障礙主要生產商
    • 北美市場規模及預測（按國家/地區分類）
    • 北美市場規模及預測（按類型分類）
    • 北美市場規模及預測（依治療方式分類）
    • 北美市場規模及預測（按測試）
    • 北美市場規模及預測（依最終用戶分類）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲凝血障礙主要生產商
    • 歐洲市場規模及預測（按國家/地區分類）
    • 歐洲市場規模及預測（按類型分類）
    • 歐洲市場規模及預測（依治療方式分類）
    • 歐洲市場規模及預測（按測試）
    • 歐洲市場規模及預測（依最終用戶分類）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區
    • 概述
    • 亞太地區凝血障礙主要生產商
    • 亞太市場規模及預測（依國家/地區分類）
    • 亞太市場規模及預測（按類型分類）
    • 亞太地區市場規模及預測（依治療方式分類）
    • 亞太市場規模及預測（按測試）
    • 亞太市場規模及預測（依最終用戶分類）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲凝血障礙主要生產商
    • 拉丁美洲市場規模及預測（按國家/地區分類）
    • 拉丁美洲市場規模及預測（按類型分類）
    • 拉丁美洲市場規模及預測（依治療方式分類）
    • 拉丁美洲市場規模及預測（按測試）
    • 拉丁美洲市場規模及預測（按最終用戶分類）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲凝血障礙主要生產商
    • MEA市場規模及預測（依國家/地區分類）
    • MEA市場規模及預測（按類型分類）
    • MEA市場規模及預測（依治療方式分類）
    • MEA市場規模及預測（按測試）
    • MEA市場規模及預測（依最終用戶分類）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 中東和非洲其他地區

第12章：主要供應商分析－凝血障礙產業

  • 競爭格局分析
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Griflos SA
    • Hoffman-La Roche Ltd
    • Bio-Rad Laboratories
    • B Braun
    • Abbott
    • Bayer AG
    • Helena Laboratories
    • Fresenius Kabi
    • Haemonetics Corporation
    • VarmX BV
    • Biogen Inc.
    • Others

第13章：360度AnalystView

第14章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5697

Coagulation Disorders Market size was valued at US$ 10,567.89 Million in 2024, expanding at a CAGR of 6.8% from 2025 to 2032.

The coagulation disorders market is driven by increasing prevalence of bleeding and clotting disorders and advances in personalized medicine such as gene therapies and recombinant clotting factors. Integration of AI in diagnostics and management optimizes treatment plans through predictive analytics and individualized monitoring is expected to generate lucrative opportunities in the market over forecast period. Additionally, digital health solutions are increasing patient convenience, improving adherence, and enhancing outcomes by facilitating remote monitoring and telemedicine consultations. However, supply chain disruptions and geographic disparities in healthcare infrastructure pose challenges to market expansion. Moreover, high treatment costs, regulatory challenges, and slower adoption of novel testing technologies are also restraining the market growth.

Coagulation Disorders Market- Market Dynamics

Rising Adoption of Gene Therapies and Personalized Medicine

Hemophilia and other rare bleeding disorders have historically required repeated infusions of recombinant or plasma-derived clotting factors. Nevertheless, these treatments are expensive, need lifelong care, and carry a risk of inhibitor development. Gene therapies now offer the potential for one-time, long-lasting correction of coagulation factor deficiencies by inserting functional copies of defective genes. For instance, in June 2023, U.S. FDA have approved gene therapies such as Roctavian (BioMarin) for Hemophilia A and Hemgenix (CSL Behring/UniQure) for Hemophilia B. Hemophilia A is a rare genetic disorder characterized by a deficiency of clotting factor VIII (FVIII), which leads to prolonged bleeding and may cause life-threatening complications such as uncontrolled internal bleeding and joint damage. Additionally, personalized medicine further complements this shift by tailoring treatment plans based on individual genetic profiles, enabling precise targeting of therapy and minimizing adverse effects. Advances in molecular diagnostics, including genetic testing and next-generation sequencing (NGS), facilitate early diagnosis and patient stratification, which enhances outcomes by matching the most appropriate therapies to patient-specific characteristics.

Coagulation Disorders Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.8% over the forecast period (2025-2032)

Based on Type segmentation, Hemophilia A is predicted to show maximum market share in the year 2024

Based on Treatment segmentation, Blood Transfusion is the leading Treatment in 2024

Based on Test segmentation, Prothrombin Time Test is the leading Test in 2024

Based on End Users segmentation, Hospitals is the leading End Users in 2024

On the basis of region, Asia Pacific is the leading revenue generator in 2024

Coagulation Disorders Market- Segmentation Analysis:

The Global Coagulation Disorders Market is segmented on the basis of Type, Treatment, Test, End Users, and Region.

The market is divided into five categories based on Type: Hemophilia A, Hemophilia B, Von Willebrand's Disease, Factor II, V, X, XII Deficiencies, and Others. Hemophilia A is a genetic disorder characterized by a deficiency of clotting factor VIII, while Hemophilia B involves a deficiency of factor IX with similar symptoms. Von Willebrand's Disease results from low or defective von Willebrand factor, affecting blood clotting and causing mucosal bleeding. Factor II, V, X, XII deficiencies are rare coagulation disorders involving other clotting factors, leading to variable bleeding symptoms.

The market is divided into three categories based on Treatment: Iron Supplementation, Blood Transfusion, and Others. Iron supplementation is used to address anemia related to chronic blood loss. On the other-hand, blood transfusion replaces lost blood and supports clotting factor restoration. Factor replacement therapy, desmopressin, clot-preserving medications, gene therapy, and non-factor therapies tailor treatment based on disorder type and severity.

Coagulation Disorders Market- Geographical Insights

The coagulation disorders market shows distinct geographical trends shaped by healthcare infrastructure, disease prevalence, and regional investments. North America dominates the market, owing to high prevalence rates of coagulation disorders, well-established healthcare systems, and robust research and development activities. Additionally, increasing investments in plasma collection centers further boost market growth. Europe holds the second-largest share, with countries like Germany, the UK, France, Italy, and Spain contributing significantly. The region experiences growth through extensive research collaborations, regulatory approvals, and high patient awareness. Aging populations and advancements in diagnostic capabilities contribute to rising demand for coagulation disorder management. The Asia-Pacific region is the fastest-growing, fueled by rising healthcare expenditures, rapid urbanization, and expanding healthcare infrastructure in China, India, and Japan. Due to restricted access to and awareness of healthcare, regions including the Middle East, Africa, and Latin America exhibit slower growth. However, they also exhibit tremendous potential as a result of ongoing healthcare advancements and international collaborations.

Coagulation Disorders Market- Competitive Landscape:

The coagulation disorders market competitive landscape is characterized by the presence of several key global players who are driving innovation through advanced therapies and diagnostic solutions. The key market players focus on developing innovative treatment options such as gene therapies, long-acting recombinant clotting factors, monoclonal antibodies, and biosimilars to improve patient outcomes and quality of life. For instance, in April 2024, Haemonetics Corporation, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TEG 6s hemostasis analyzer system's Global Hemostasis-HN assay cartridge. This new cartridge expanded the TEG 6s system's viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries and liver transplantation. Additionally, the adoption of plasma-free recombinant products and advancements in gene editing technologies like CRISPR are key trends shaping competition. Companies are also investing in point-of-care diagnostic tools and wearable coagulation monitoring devices, fostering a shift towards personalized and convenient patient care. Strategic collaborations, mergers, and acquisitions are common as companies strive to expand their product portfolios and regional presence.

Recent Developments:

In July 2025, Bio-Rad Laboratories, Inc. declared the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include Bio-Rad's QX Continuum droplet digital PCR (ddPCR) system, designed for translational research applications with a simplified, qPCR-like workflow, four-color multiplexing, and up to eight discrete thermal profiles per plate. With this launch, Bio-Rad's expanded portfolio of instruments, reagents, software, and services broadens its footprint in genomics research and applied science markets

In September 2025, VarmX B.V. is collaborated with CSL for the development of VMX-C001, a treatment restoring coagulation in patients on FXa DOACs. This treatment is intended to be administered as a single-dose infusion in emergency settings, such as severe bleeding or urgent surgery, where quick restoration of clotting is critical.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL COAGULATION DISORDERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Griflos S.A
  • Hoffman-La Roche Ltd
  • Bio-Rad Laboratories
  • B Braun
  • Abbott
  • Bayer AG
  • Helena Laboratories
  • Fresenius Kabi
  • Haemonetics Corporation
  • VarmX B.V.
  • Biogen Inc.
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand's Disease
  • Factor II, V, X, XII Deficiencies
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Iron Supplementation
  • Blood Transfusion
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY TEST- MARKET ANALYSIS, 2019 - 2032

  • Complete Blood Count (CBC)
  • Platelet Aggregation Test
  • Fibrinogen Assay
  • Prothrombin Time Test
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY END USERS- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Blood Banks
  • Others

GLOBAL COAGULATION DISORDERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Coagulation Disorders Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Coagulation Disorders Market Snippet by Type
    • 2.1.2. Coagulation Disorders Market Snippet by Treatment
    • 2.1.3. Coagulation Disorders Market Snippet by Test
    • 2.1.4. Coagulation Disorders Market Snippet by End Users
    • 2.1.5. Coagulation Disorders Market Snippet by Country
    • 2.1.6. Coagulation Disorders Market Snippet by Region
  • 2.2. Competitive Insights

3. Coagulation Disorders Key Market Trends

  • 3.1. Coagulation Disorders Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Coagulation Disorders Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Coagulation Disorders Market Opportunities
  • 3.4. Coagulation Disorders Market Future Trends

4. Coagulation Disorders Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Coagulation Disorders Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Coagulation Disorders Market Landscape

  • 6.1. Coagulation Disorders Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Coagulation Disorders Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Hemophilia A
    • 7.1.3. Hemophilia B
    • 7.1.4. Von Willebrand's Disease
    • 7.1.5. Factor II, V, X, XII Deficiencies
    • 7.1.6. Others

8. Coagulation Disorders Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 8.1.2. Iron Supplementation
    • 8.1.3. Blood Transfusion
    • 8.1.4. Others

9. Coagulation Disorders Market - By Test

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Test, 2024 & 2032 (%)
    • 9.1.2. Complete Blood Count (CBC)
    • 9.1.3. Platelet Aggregation Test
    • 9.1.4. Fibrinogen Assay
    • 9.1.5. Prothrombin Time Test
    • 9.1.6. Others

10. Coagulation Disorders Market - By End Users

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End Users, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Diagnostic Centers
    • 10.1.5. Blood Banks
    • 10.1.6. Others

11. Coagulation Disorders Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Coagulation Disorders Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Coagulation Disorders Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Coagulation Disorders Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Coagulation Disorders Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Coagulation Disorders Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Test, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End Users, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Coagulation Disorders Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Griflos S.A
    • 12.2.2. Hoffman-La Roche Ltd
    • 12.2.3. Bio-Rad Laboratories
    • 12.2.4. B Braun
    • 12.2.5. Abbott
    • 12.2.6. Bayer AG
    • 12.2.7. Helena Laboratories
    • 12.2.8. Fresenius Kabi
    • 12.2.9. Haemonetics Corporation
    • 12.2.10. VarmX B.V.
    • 12.2.11. Biogen Inc.
    • 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us